Promising Efficacy of AT101 CAR-T for Blood Cancer
April 18, 2023 — 02:00 CST
This Data Is Locked!
This area is available only to Subscribers.
SEOUL, South Korea, April 18, 2023 /PRNewswire/ -- AbClon, a South Korean biotech firm, presented non-clinical and phase 1 interim results of its AT101 novel CAR-T... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
